Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : Trader J's Inner Circle -- Ignore unavailable to you. Want to Upgrade?

To: Poet who wrote (9310)	2/18/1999 2:57:00 PM
From: Mike McFarland	Read Replies (1) \| Respond to of 56535

I beat you to the correction;-) _____ Hmmm, I need to flesh this post out with something...why, how about a little biotech chit chat? Today Genentech announced that the 178-patient Phase II clinical trial of the company's recombinant human vascular endothelial growth factor (rhVEGF165) protein did not meet its primary objectives. I don't know that this is neccessarily the problem, but it seems to be there are a whole gaggle of molecules that you would like to place in the body for treating various maladies. One of the problems is that the really interesting molecules are really large and complicated...and delivery is messy--eating doesn't work, you break down the molecule and it will most certainly never reach it's target. The blood brain barrier is another example of why large molecules don't get where they need to go. My second largest holding is CTII, CytoTherapeutics. They have encapsulation technology and plenty o' patents, plus the stem cell angle as well. recap.com